A Phase 1, Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment.
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Lorcaserin (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Arena Pharmaceuticals
- 29 Mar 2017 Results assessing pharmacokinetics and tolerability of Lorcaserin in different populations in three studies (NCT00828581, NCT00828438, and NCT00828932) published in the Clinical Therapeutics
- 30 Jul 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 30 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.